<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: This was a retrospective cohort study of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients, to evaluate the association between initial <z:chebi fb="0" ids="6801">metformin</z:chebi> or sulphonylurea treatment and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Patients identified in the UK Clinical Practice Research Datalink (CPRD), previously General Practice Research Database, during 1995-2008 who were initially stabilized on OHA monotherapy, including <z:chebi fb="0" ids="6801">metformin</z:chebi>, sulphonylurea, <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs) or meglitinides, were included in the cohort </plain></SENT>
<SENT sid="2" pm="."><plain>New diagnoses of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, including <z:e sem="disease" ids="C1698088" disease_type="Neoplastic Process" abbrv="">malignant solid tumours</z:e> and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, occurring during the follow-up were identified from the cohort </plain></SENT>
<SENT sid="3" pm="."><plain>Age-standardized incidence rates were estimated and compared between <z:chebi fb="0" ids="6801">metformin</z:chebi> and sulphonylurea exposure groups </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The age standardized incidences of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> were 7.5 and 8.5 per 1000 person-years for the <z:chebi fb="0" ids="6801">metformin</z:chebi> and sulphonylurea exposure groups, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>After adjusting for potential confounders, the hazard ratios (HR) for <z:e sem="disease" ids="C1698088" disease_type="Neoplastic Process" abbrv="">malignant solid tumours</z:e> and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> were 1.06 (95% CI: 0.98, 1.15) and 0.98 (95% CI: 0.67, 1.43) for sulphonylurea group as compared to the <z:chebi fb="0" ids="6801">metformin</z:chebi> group, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>For individual <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, the HRs were 1.17 (95% CI: 0.95, 1.44), 1.04 (95% CI: 0.83, 1.31) and 0.88 (95% CI: 0.71, 1.11) for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: This study provides evidence that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence in the first few years after starting <z:chebi fb="0" ids="6801">metformin</z:chebi> or sulphonylurea therapy in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients is not much affected by choice of hypoglycaemic drug class </plain></SENT>
</text></document>